Acardioprotective drug nikorandil in coronary heart disease

  • Authors: Malysheva A.M.1, Martsevich S.Y.1, Ginzburg M.L.1, Malysheva AM2, Martsevich SY.2,3, Ginzburg ML4
  • Affiliations:
    1. Prophylactic Medicine Research Center, Moscow
    2. State I.M. Sechenov First Medical University
    3. District hospital N 2, Lyubertsy
  • Issue: Vol 83, No 9 (2011)
  • Pages: 14-19
  • Section: Editorial
  • URL: https://ter-arkhiv.ru/0040-3660/article/view/30891
  • Cite item

Abstract


Nicorandil, opener of potassium channels, was studied in Russia and abroad. Its cardioprotective, anti-ischemic, pharmacokinetic and pharmacodynamic properties are reviewed as well as side effects and area of application in patients with stable coronary heart disease (CHD). The trial have found efficacy of nicorandil in prevention of anginal attacks. Also, the drug increases exercise tolerance. Administration of nicorandil is indicated before intervention on coronary arteries for reproduction of the effect of myocardial preconditioning. Nicorandil is recommended for treatment of patients with chronic stable coronary heart disease.

About the authors

Anna Mikhaylovna Malysheva

Email: amalysheva@ Gnicpm.ru

Sergey Yur'evich Martsevich

Moisey L'vovich Ginzburg

A M Malysheva

Prophylactic Medicine Research Center, Moscow

Prophylactic Medicine Research Center, Moscow

S Yu Martsevich

Prophylactic Medicine Research Center, Moscow; State I.M. Sechenov First Medical University

Prophylactic Medicine Research Center, Moscow; State I.M. Sechenov First Medical University

M L Ginzburg

District hospital N 2, Lyubertsy

District hospital N 2, Lyubertsy

References

  1. Fox K., Garcia M. A., Ardissino D. et al. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27 (11): 1341-1381.
  2. Чазов Е. И., Беленков Ю. Н., ред. Рациональная фармакотерапия сердечно-сосудистых заболеваний: Руководство для практикующих врачей. М.: Литерра; 2005.
  3. Фармакотерапия хронических сердечно-сосудистых заболеваний: Руководство для врачей / Ольбинская Л. И., Морозова Т. Е., Сизова Ж. М. и др. М.: Медицина; 2006.
  4. Елисеев О. М. Ивабрадин (кораксан). Еще один подход к борьбе с ишемией миокарда у больных ишемической болезнью сердца. Тер. архив. 2006, 9: 78-86.
  5. Haghfelt T. H. Ivabradine - a medical alternative for patients with chronic stable angina pectoris. Ugeskr. Laeg. 2006; 168 (46): 3991-3993.
  6. Taira N. Nicorandil as a hybrid between nitrates and potassium channel activators. Am. J. Cardiol. 1989; 63 (21): 18J- 24J.
  7. Kinoshita M., Sakai K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther. 1990; 4 (4): 1075- 1088.
  8. IONA Study Grup. Effect of nicorandil on coronary events in patients with stable angina: the Impact Of Nicorandil in Angina (IONA): randomized trial. Lancet. 2002; 359 (9314): 1269-1275.
  9. Roland E. Safety profile of an anti-anginal agent with potassium channel opening activity: an overview. Eur. Heart. J. 1993; 14 (Suppl. B): 48-52.
  10. Maczewski M., Bercewicz A. The role of adenosine and ATP-sensitive potassium channels in the protection afforded by ischemic preconditioning against the post-ischemic endothelial dysfunction in guinea-pig hearts. J. Mol. Cell. Cardiol. 1998; 30: 1735-1747.
  11. Ren Z., Yang Q., Floten H. S. et al. ATPsensitive potassium channel openers may mimic the effects of hypoxic preconditioning on the coronary artery. Ann. Thorac. Surg. 2001; 71: 642-647.
  12. Meany T. B., Richardson P., Camm A. J. et al. Exercise capacity after single and twice-daily doses of nicorandil in chronic stable angina pectoris. Am. J. Cardiol. 1989; 63 (21): 66J-70J.
  13. Grover G. J. Pharmacology of ATP-sensitive potassium channel (KATP) openers in models of myocardial ischemia and reperfusion. Can. J. Physiol. Pharmacol. 1997; 75: 309-315.
  14. Ohno Y., Minatoguchi S., Uno Y. et al. Nicorandil reduces myocardial infarct size by opening the KATP channel in rabbits. Int. J. Cardiol. 1997; 62: 181-190.
  15. Schultz J. E., Yao Z., Cavero I., Gross G. J. Glibenclamide-induced blockade of ischemic preconditioning is time dependent in intact rat heart. Am. J. Physiol. 1997; 272: H2607-H2615.
  16. Miura T., Liu Y., Kita H. et al. Roles of mitochondria ATP-sensitive K channels and PKC in anti-infarct tolerance afforded by adenosine A1 receptor activation. J. Am. Coll. Cardiol. 2000; 35: 238-245.
  17. Fukuda H., Luo C. S., Guo L. L. et al. The effect of KATP channel activation on myocardial cationic and energetic status during ischemia and reperfusion: Role in cardioprotection. J. Mol. Cell. Cardiol. 2001; 33: 545-560.
  18. Matsuo H., Watanabe S., Segawa T. et al. Evidence of pharmacologic preconditioning during PTCA by intravenous pretreatment with ATPsensitive K+ channel opener nicorandil. Eur. Heart. J. 2003; 24 (14): 1296-1303.
  19. Iliodromitis E. K., Cokkinos P., Zoga A. et al. Oral nicorandil recaptures the waned protection from preconditioning in vivo. Br. J. Pharmacol. 2003; 138 (6): 1101-1106.
  20. Kato T., Kamiyama T., Maruyama Y. et al. Nicorandil, a potent cardioprotective agent, reduces QT dispersion during coronary angioplasty. Am. Heart. J. 2001; 141: 940-943.
  21. Ishii H., Toriyama T., Aoyama T. et al. Efficacy of oral nicorandil in patients with end-stage renal disease: A retrospective chart view after coronary angioplasty in Japanese patients receiving hemodialysis. Clin. Ther. 2007; 29: 110-122.
  22. Kitakaze M., Asakura M., Kim J. et al. Human atrial natriuretic peptide and nicorandil as adjuncts to reperfusion treatment for acute myocardial infarction (J-WIND): two randomised trials. Lancet. 2007; 370: 1483-1493.
  23. THE EMIP-FR GROUP. Effect of 48-h intravenous trimetazidine on short- and long-term outcomes of patients with acute myocardial infarction, with and without thrombolytic therapy Eur. Heart J. 2000; 21: 1537-1546.
  24. Morrow D. A. et al. Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. J. A. M. A. 2007; 297 (16): 1775-1783.
  25. Ishii H., Ichimiya S., Kanashiro M. et al. Impact of a single intravenous administration of nicorandil before reperfusion in patients with ST-segment-elevation myocardial infarction. Circulation 2005; 112: 1284-1288.
  26. Shigeo Horinaka, Akihisa Yabe, Hiroshi Yagi et al. Effects of nicorandil on cardiovascular invents in patients with coronary artery disease in the Japanese Coronary Artery Disease (JCAD) Study. Circ. J. 2010; 74: 503-509.
  27. Poole-Wilson P. A., Lubsen J., Kirwan B. A. et al. Effect of long acting nifedipine on mortality and cardiovascular morbidity in patients with stable angina requiring treatment (ACTION trial): randomised controlled trial. Lancet. 2004; 364: 849-857.
  28. Fox K., Ford I., Tendere M., Ferrari R. BEAUTIFUL Investigators. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372 (9641): 807-816.
  29. Сизова Ж. М., Ших Е. В., Захарова В. Л., Смирнова Е. В. Современная фармакотерапия стабильной стенокардии: возможности и перспективы применения никорандила. Рационал. фармакотер. в кардиол. 2010; 6 (3): 455-460.
  30. Бадриддинова Л. Ю., Юргель Н. В., Кукес В. Г., Павлова Л. И. Фармакодинамика и клиническая эффективность никорандила. Клин. фармакол. и тер. 2009; 6: 124-125.
  31. Викторов А. П., Лугай М. И., Дмитриева Т. Ю. Антиишемическая и антигипертензивная эффективность никорандила - модулятора калиевых каналов. Украiн. медичн. часопис. 1999; 5: 56-60.
  32. Markham A., Plosker G. L., Goa K. L. Nicorandil. An updated review of its use in ischemic heart disease with emphasis on its cardioprotective effects. Drugs 2000; 60: 955-974.
  33. Simpson D., Wellington K. Nicorandil: A review of its use in the management of stable angina pectoris, including high risk patients. Drugs 2004; 64: 1941-1955.
  34. Рекомендации ВНОК "Рациональная фармакотерапия больных сердечно-сосудистыми заболеваниями". В составе рабочей группы: Марцевич С. Ю., Аничков Д. А., Белолипецкая В. Г., Концевая А. В., Кутишенко Н. П., Лукина Ю. В., Толпыгина С. Н., Шилова Е. В., Якусевич В. В. Кардиоваск. тер. и профилакт. 2009; 6 (прил. 4): 38.

Statistics

Views

Abstract - 52

Cited-By


Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
 

Address of the Editorial Office:

  • Novij Zykovskij proezd, 3, 40, Moscow, 125167

Correspondence address:

  • Novoslobodskaya str 31c4., Moscow, 127005, Russian Federation

Managing Editor:

 

© 2018 "Consilium Medicum" Publishing house

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies